Abbott Laboratories (NYSE: ABT) has reported E.P.S. of $0.70 for its first fiscal quarter (ending March 31) versus $0.75 for the same period a year ago. For the latest four quarters through March 31, E.P.S. were $3.23 compared to $3.31 a year ago.
Recent Price Action
Abbott Laboratories (NYSE: ABT) stock closed at $105.90 on 4/17/24 after a decline of -3.0%. Moreover, this decline was accompanied by exceptionally high trading volume at 206% of normal. The stock has declined -5.8% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
ABT’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be a major Value Builder.
Abbott Laboratories has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Abbott Laboratories has a poor Appreciation Score of 19 but a slightly positive Power Rating of 61, triggering the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment